- Our Company
- Aerospace & Industrial
- CMF & Orthopedics
- Biomedical Manufacturing
- News & Events
OPM Gets $150,000 Grant to Develop Infection Treatments for 3D Printed Implants
November 19th, 2014
November 19th, 2014
Oxford Performance Materials Inc. has revealed it has received a three-year $150,000 grant from the National Institutes of Health to deliver new approaches in the treatment of infections related to implanted devices from advanced applications of 3D printed poly-ether-ketone-ketone.
The NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases provided the funding to improve the treatment of infections associated with artificial hips, knees and other implanted devices. The grant will support research in developing new approaches to the delivery of antibiotics through OPM's 3D printed PEKK implants.
"Device related infections are a burdensome clinical issue that results in prolonged patient suffering, increased mortality, and are expected to cost $12 billion per year by 2015,” explained Dr. Adam Hacking, PhD, Chief Scientific Officer, at OPM. “With this support from the NIH, we have the potential to rapidly advance treatment for bone and joint infections, reduce healthcare costs, reduce patient suffering and improve patient care."
This multidisciplinary research program involves established and productive experts from the Dept. of Orthopedics at the Massachusetts General Hospital, Harvard Medical School and the School of Engineering and Applied Sciences at Harvard University.
Dr. Hacking added: "3D printing has enabled the combination of a load-bearing implantable material, PEKK, with the simplicity, flexibility and availability of perfusable drug delivery systems.”
OPM recently began a joint research programme with Yale University to develop innovative and cost-effective 3D printed biomedical technologies and applications, furthering the application of 3D printing in the healthcare industry.
About Oxford Performance Materials, Inc.
Oxford Performance Materials (OPM) is a recognized leader in 3D printing and high performance additive manufacturing (HPAM™). OPM has developed a range of advanced materials technology focused on the high performance polymer, poly-ether-ketone-ketone (PEKK). OPM is the first company to successfully apply additive manufacturing solutions using PEKK by utilizing the company’s proprietary OXPEKK® formulation and delivers enterprise level, functional end-use products to the biomedical, aerospace and industrial markets. A pioneer in personalized medicine, OPM became the only company to receive FDA clearance to manufacture 3D printed patient‐specific polymeric implants for its cranial prostheses line in February 2013, and its Biomedical division received a second 510(k) for its patient-specific facial implants in July 2014. OPM's Aerospace & Industrial division has been fulfilling critical development contracts with its OXFAB® technologies for parts in a range of aircraft applications in commercial, defense, and space with its proprietary HPAM™ technology. For more information, please visit: http://www.oxfordpm.com/
Oxford Performance Materials